Navigation Links
Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
Date:5/15/2012

d a variable risk of transformation to acute myeloid leukemia.  It is estimated that MDS affects approximately 300,000 people worldwide.  According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years.  MDS patients often require multiple blood transfusions to manage their disease.

Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1, which leads to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells; this mechanism induces cancer cell death, or apoptosis, in human leukemia cell lines. Telintra is also being evaluated in a Phase 2 clinical trial in Revlimid refractory and resistant deletion 5q MDS patients and a Phase 2b clinical trial in non-deletion 5q MDS patients.  Additional information about Telintra is available at www.telik.com.

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical-stage drug development company focused on discovering and developing small-molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome, followed by Telcyta®, a cancer-activated prodrug for the treatment of a variety of cancers.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small-molecule drug candidates.

This press release contains "forward-looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating MDS, whether Telintra treatment results in hematologic improvement in patients with MDS, whether Telintra reduces the need for, or offer
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Regains Compliance With Minimum Bid Price Requirement
2. Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
3. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
4. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
5. Telik Announces Third Quarter 2011 Financial Results
6. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
7. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
9. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
10. Telik Announces First Quarter 2011 Financial Results
11. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Immune Pharmaceuticals, Inc. ... Dr. Daniel Teper , will present live at ... 6, 2015 TIME:   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... interactive online event where investors are invited to ask ... presentation hall as well as the association,s "virtual trade ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... , July 31, 2015  In today,s ever-changing marketplace, ... are increasingly mobile, increasingly connected, and increasingly impatient with ... of customer interaction channels and tools is driving call ... media. According to research by benchmarking ... counter (OTC) segment in a call center study realize ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
... , ABBOTT PARK, Ill., July 28 ... Food and Drug Administration (FDA) approval for two new ... SIMCOR dosage strengths combine 40 mg of simvastatin – ... either 500 mg or 1,000 mg of niacin extended-release. ...
... In FDLI,s latest monograph, Selling Pharmaceuticals and Biologics to ... , Joy Sturm , Allison Pugsley ... Hogan Lovells US LLP detail how pharmaceutical and ... price calculation requirements. The 73-page monograph (Volume 1, #5) succinctly ...
Cached Medicine Technology:Abbott's SIMCOR ® ( niacin extended-release / simvastatin ) Receives FDA Approval for New Dosage Strengths 2Abbott's SIMCOR ® ( niacin extended-release / simvastatin ) Receives FDA Approval for New Dosage Strengths 3New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Health notes that while an overwhelming number of Hispanics believe people can ... The overwhelming 70 percent of participants queried said making diet changes was important. ...
(Date:8/3/2015)... ... 2015 , ... Dental practice in Los Angeles , Sunset Plaza Dental, ... that general health emergencies, such as broken arms or a heart attack, should be ... turn to during a dental emergency. This is important, because dental trauma is extremely ...
(Date:8/3/2015)... ... , ... The art of preparing and cooking food comes naturally to some. ... age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is ... Persian Kitchen with the world. , Since Americans tend to be undereducated about Persian ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has ... with access to the tactics, techniques and practices required to design and develop ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... trend has emerged among U.S. emergency rooms in recent years, according to the American ... 2012, the number of dental emergency visits went from 1.1 million in a single ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... without hepatocellular carcinoma (HCC) derive a greater survival benefit ... for a deceased donor liver transplant (DDLT). The study ... journal published by Wiley-Blackwell on behalf of the American ... survival benefit from LDLT remains significant across the range ...
... , TUESDAY, Sept. 27 (HealthDay News) -- ... lethal prostate cancers have been identified by scientists who ... of cancers. The team also identified several instances ... that can give the cancers resistance to therapies commonly ...
... negative effects that premature birth can have on the lungs ... as those born extremely prematurely but may be reversed in ... research will be presented at the European Respiratory Society Annual ... lasts 40 weeks, which allows enough time for the infant ...
... For all long-term care residents, pressure reduction foam mattresses ... mattresses, with average savings of $115 per resident, the ... cost-effective 94% of the time compared to soap and ... The clinical benefits of foam cleansers for bedsores, or ...
... , MONDAY, Sept. 26 (HealthDay News) -- Older women ... within a year because of the fracture, not an underlying health ... that it is the hip fracture, and not just poor health, ... author Dr. Teresa Hillier, a senior investigator at the Kaiser Permanente ...
... Doctors and other medical professionals occasionally joke about their ... but some joking between medical professionals is not only ... in the Hastings Center Report . The ... and comedy: she is an assistant professor in the ...
Cached Medicine News:Health News:Living donor liver transplantation improves survival over deceased donor transplants 2Health News:Lung function of moderately premature babies is reduced at 8-9 years but may improve with age 2Health News:Prevention of bedsores in long-term care homes cost-effective, study shows 2Health News:Hip Fracture May Raise a Woman's Risk of Earlier Death 2Health News:Is gallows humor in medicine wrong? 2
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... Captia™ Legionella pneumophila IgG/IgM Enzyme-Linked ... for the qualitative detection of ... to Legionella pneumophila (Legionella) serogroups ... with clinical suspicion of Legionella ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: